InvestorsHub Logo
Followers 21
Posts 980
Boards Moderated 0
Alias Born 03/20/2019

Re: None

Tuesday, 11/19/2019 4:40:19 PM

Tuesday, November 19, 2019 4:40:19 PM

Post# of 426489
Oppenheimer analyst favors Acasti over AMRN. SMH He does not believe Acasti will need an outcome trial.

Look at the increase in Acasti in the after hour market compared to the hit to AMRN.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News